Tesofensine

InvestigationalMetabolic ResearchWeight & metabolicBrain, mood & sleep
5.0

Neutral, BioHarmony verdict

BioHarmony score 5.0 out of 10

Tesofensine is a small-molecule triple monoamine reuptake inhibitor that produced strong Phase 2 weight loss for obesity, about 9 to 11 percent at 24 weeks per Astrup 2008, roughly double the obesity drugs of its era. The catch is the mechanism: it raises heart rate, development stalled over cardiovascular and mood concerns, the pivotal paper carries a journal Expression of…

Read full report

What is Tesofensine?

Tesofensine is a lab-made small molecule that blocks the brain's reuptake of all three major monoamines, serotonin, noradrenaline, and dopamine, at once. That triple block raises the levels of those neurotransmitters, and the dominant result is that you stop feeling hungry. It is a triple monoamine reuptake inhibitor, and it is not a peptide.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Blocks reuptake of all three central monoamines, suppressing appetite while raising sympathetic tone

Safety watch-outs

  • Rising resting heart rate or blood pressure (the development-stalling cardiovascular signal): stop and consult a clinician.
  • New or worsening anxiety, irritability, low mood, or insomnia (the monoamine and psychiatric signal): stop and reassess.
  • Any cardiovascular disease, hypertension, arrhythmia, or elevated baseline resting heart rate: do not use.
  • History of anxiety, mood disorder, or substance-use disorder: do not use without close supervision, given the stimulant-class mechanism.
  • Grey-market or research-chemical material of unverified purity and dose: do not use.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Tesofensine yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved U.S. product is identified in the reviewed source set

Tesofensine has completed Phase 3 obesity studies in Mexico through Saniona's partner Medix. Saniona describes it as an investigational candidate; completion of a trial program is not marketing approval.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.